GNCA · Genocea Biosciences, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $39.02M | $33.96M | $26.95M | $25.21M | $39.20M | $34.65M |
| SG&A | $14.71M | $14.39M | $12.04M | $14.31M | $13.43M | $15.43M |
| Total Operating Expenses | $53.73M | $48.35M | $38.99M | $39.52M | $55.26M | $48.48M |
| D&A | $1.56M | $1.14M | $1.10M | $1.09M | $1.52M | $1.81M |
| Operating Income | ($52.09M) | ($46.99M) | ($38.99M) | ($39.52M) | ($55.26M) | ($48.24M) |
| Interest Expense | $1.12M | $1.38M | $946.0K | $1.02M | $1.71M | $1.74M |
| Income Tax | - | - | - | - | - | - |
| Net Income | ($33.20M) | ($43.71M) | ($38.95M) | ($27.81M) | ($56.71M) | ($49.57M) |
| EPS - Basic | ($0.48) | ($0.98) | - | - | - | - |
| EPS - Diluted | ($0.48) | ($1.11) | - | - | - | - |
Balance Sheet
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $37.15M | $79.77M | $40.13M | $26.36M | $12.27M | $27.42M |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $500.0K | $534.0K | $553.0K | $1.66M | $3.52M | $3.04M |
| Current Assets | $41.82M | $82.23M | $41.58M | $27.06M | $13.08M | $64.29M |
| Total Assets | $55.97M | $98.49M | $52.61M | $31.11M | $17.49M | $69.90M |
| Current Liabilities | $18.68M | $25.00M | $6.28M | $10.73M | $15.78M | $10.37M |
| Long-term Debt | $4.15M | $0 | $13.41M | $9.56M | $7.65M | $13.81M |
| Total Liabilities | $28.89M | $89.51M | $27.57M | $23.78M | $23.54M | $24.36M |
| Stockholders' Equity | $27.07M | $8.98M | $25.04M | $7.33M | ($6.05M) | $45.54M |
| Retained Earnings | ($407.86M) | ($374.67M) | ($330.95M) | ($292.00M) | ($264.19M) | ($207.48M) |
Cash Flow
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($45.37M) | ($41.65M) | ($41.23M) | ($41.23M) | ($47.60M) | ($41.84M) |
| Investing Cash Flow | ($3.21M) | ($2.56M) | ($131.0K) | ($131.0K) | $34.91M | $50.71M |
| Financing Cash Flow | $5.96M | $83.85M | $55.45M | $55.45M | ($2.46M) | $1.29M |
| CapEx | $3.29M | $2.58M | $1.14M | $241.0K | $1.18M | $2.54M |
| Free Cash Flow | ($48.66M) | ($44.24M) | ($42.37M) | ($41.48M) | ($48.78M) | ($44.37M) |
Ratios
| Metric | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | 1.47 | 1.01 | 1.09 | 1.49 | 0.86 | 0.90 |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -59.3% | -44.4% | -74.0% | -89.4% | -324.3% | -70.9% |
| Return on equity | -122.6% | -486.7% | -155.5% | -379.2% | 937.4% | -108.9% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 2.24 | 3.29 | 6.62 | 2.52 | 0.83 | 6.20 |
| Quick ratio | 2.24 | 3.29 | 6.62 | 2.52 | 0.83 | 6.20 |
| Cash ratio | 1.99 | 3.19 | 6.39 | 2.46 | 0.78 | 2.64 |
| Leverage | ||||||
| Debt / Equity | 0.15 | 0.00 | 0.54 | 1.30 | -1.26 | 0.30 |
| Debt / Assets | 0.07 | 0.00 | 0.25 | 0.31 | 0.44 | 0.20 |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | -46.5x | -34.0x | -41.2x | -38.7x | -32.4x | -27.8x |
| Equity multiplier | 2.07 | 10.97 | 2.10 | 4.24 | -2.89 | 1.53 |
| Liabilities / Assets | 0.52 | 0.91 | 0.52 | 0.76 | 1.35 | 0.35 |
| Efficiency | ||||||
| Asset turnover | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | -10.9% | -20.5% | 1.3% | 28.5% | -14.5% | -16.6% |
| Net income growth (YoY) | 24.1% | -12.2% | -40.1% | 51.0% | -14.4% | -16.7% |
| EPS growth (YoY) | 56.8% | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | -10.0% | -4.4% | -2.2% | 15.0% | -9.9% | -7.9% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | 201.4% | -64.1% | 241.4% | - | - | -49.2% |
Stability scores
Piotroski F-score
FY 2021 · 9-point quality
0/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✗Cash flow > net income
- ✗Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing GENOCEA BIOSCIENCES against the 5 most active filers in the same SIC group.